GENE ONLINE|News &
Opinion
Blog

2019-07-09| StartupsTechnology

Philadelphia-based Stem cell startup secures US$250 million funding

by Rajaneesh K. Gopinath
Share To

By Rajaneesh K. Gopinath, Ph.D.

Three years since launching BlueRock Therapeutics with a $225 million series A funding, Bayer and Versant Ventures are once again firmly investing in stem cell technology by launching another startup along with AG Fujifilm Cellular Dynamics.

 

Century Therapeutics, a company that is developing cancer treatments through its induced Pluripotent Stem Cell (iPSC)-based allogeneic cell therapy platform, emerged from stealth mode by receiving millions in financing. Originally founded by Versant ventures last year, the Philadelphia-based company is set to receive US$215 million from Bayer’s venture capital arm, Leaps and US$35 million from Versant and AG Fujifilm Cellular Dynamics (FCDI).

 

An Edge Over First-Generation Cell Therapies

While, existing cell therapies are based majorly on reengineering and reinfusing immune cells extracted from individual patient donors at regular intervals, Century’s iPSC-based platform is set to take advantage of the unlimited self-renewing capacity of pluripotent stem cells. This would make the technology much cheaper and time saving as multiple extraction steps could be eliminated.

Carlo Rizzuto a Versant partner and Century’s director expressed his thoughts. “Versant believes that allogeneic reagents represent the next wave of innovation in cell therapy and created Century to engineer truly off-the-shelf products to treat both hematologic and solid tumors,” he said. “Today’s financing marks an important milestone in our effort to enable cell therapies to treat a much broader array of cancer patients.”

San-Diego based Fate therapeutics is another company that develops a similar cell therapy, but its manufacturing procedure of iPS-derived cells is different in approach.

 

FCDI – Primary Manufacturer of Century’s iPSC

Century therapeutics was built on the discoveries of co-founders Marcela Maus, MD, Ph.D., assistant professor of medicine at Harvard Medical School and Hiro Nakauchi, MD, Ph.D., professor of genetics at Stanford University School of Medicine. Soon after the launch, the company partnered with FCDI, a subsidiary of Fujifilm Corporation, to develop iPSC-derived immune effector cells for cancer. FCDI will serve as Century’s primary manufacturer, possessing a well optimized iPSC platform with the latest reprograming technology that uses genome integration-free methods to generate GMP grade iPSC lines.

“Fujifilm’s mission is to bring new value to society through innovation and the creation of new technologies, products and services. We are confident that FCDI’s cutting edge iPSC technologies and promising regenerative medicine solutions currently under development, can create new value to fulfill unmet medical needs and improve the lives of patients around the world,” said Toshikazu Ban, Corporate Vice President of Fujifilm Corporation. “By accelerating development of new cancer immunotherapies using allogeneic iPSC through Century, we aim to deliver the therapy to patients as soon as possible.”

 

Bayer’s Ever-Growing List of External Investment Ventures

This deal marks the eighth investment of Bayer’s venture capital arm, Leaps. It had partnered earlier with Versant ventures back in 2016 to finance BlueRock Therapeutics to develop iPSC-based therapies for myocardial infarction (MI) and Parkinson’s disease. Other notable joint ventures include Casebia Therapeutics (with CRISPR therapeutics) and Joyn Bio (with Gingko Bioworks).

Dr. Juergen Eckhardt, head of Leaps shared his excitement on the deal. “We are very excited about the potential of Century’s platform. It represents a unique opportunity in the development of next generation cell therapies that promise to address previously incurable cancers” he said.

 
References
  1. https://www.centurytherapeutics.com/media/downloads/Century-Launch-PR_7.1.19_FINAL3.pdf
  2. https://www.biocentury.com/bc-extra/financial-news/2019-07-01/versant-bayer-bet-big-ips-cells-tackle-price-efficacy-car-
  3. http://www.bioworld.com/content/century-secures-250m-ipsc-based-allogeneic-cell-therapy-targeting-cancer-0

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
How Genetics Might Affect PTSD Susceptibility
2022-10-27
Cell Therapy as a Pillar of Future Therapeutics, an Interview with Alex Huang, Vice President and Head of Cell Therapy at BeiGene
2022-10-05
Big Pharma-Backed Capstan Launches With $165 Million To Combine Cell Therapy And mRNA Technology
2022-09-15
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!